NOX1 and chronic obstructive pulmonary disease: Our findings therefore strongly demonstrate potential therapeutic application and efficacy of NOX1/NOX4 inhibition in diminishing these oxidative and inflammatory responses induced by ACS exposure, whereas targeting all of the NOX isoforms NOX1/2/4/5 might be necessary to treat COPD at the later stage.